Innovative Genomic Profiling in HR+/HER2- Metastatic Breast Cancer

In this episode of OncoTalks, Dr. Mia Levy and Dr. Paul Conkling discuss new FDA-approved treatments and therapies for HR-positive, HER2-negative metastatic breast cancer. Discover innovative genomic testing techniques that are changing the identification of mutations, paving the way for more precise treatment strategies. Tune in as we spotlight advancements in personalized breast cancer care and learn about the advantages of liquid biopsy testing. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.